Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials AI-Driven Patient Identification and Recruitment Closing Panel: Beyond “One Disease At a Time”: Platform Approaches to Accelerate Gene Therapy Trials Solutions for Trial Design Challenges in Rare Disease Trials
Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials AI-Driven Patient Identification and Recruitment Closing Panel: Beyond “One Disease At a Time”: Platform Approaches to Accelerate Gene Therapy Trials Solutions for Trial Design Challenges in Rare Disease Trials
